Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
new york blog main
41
×
biotech
new york top stories
boston blog main
boston top stories
national top stories
san francisco blog main
san francisco top stories
raleigh-durham blog main
san diego blog main
clinical trials
raleigh-durham top stories
seattle blog main
seattle top stories
national
san diego top stories
texas top stories
wisconsin blog main
wisconsin top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
texas blog main
boulder/denver blog main
boulder/denver top stories
fda
cancer
startups
amgen
deals
europe blog main
europe top stories
merck
investing
regeneron pharmaceuticals
glaxosmithkline
novartis
What
roundup
bio
drug
medicines
new
drugs
fda
ipo
biotech
cancer
cholesterol
companies
days
life
therapeutics
week
ceo
ipos
market
medicine
research
science
ago
aims
biotechs
brings
deal
develop
long
lowering
medco
medical
monday
patients
pipeline
plan
pricing
sciences
street
tests
Language
unset
41
×
Current search:
" new york blog main "
×
unset
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Novome Lands $33M to Tweak a Gut Microbe Into a Metabolic Therapy
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Veracyte Aims to Expand Diagnostics Reach With $50M NanoString Deal
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICER’s Fire & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
5 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
5 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Pelosi, Dems Unveil Price Plan: Are 25 Drugs Enough for Negotiation?
@xconomy.com
5 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
5 years ago
SpringWorks and Satsuma Boost This Week’s Biotech IPO Haul to $595M
@xconomy.com
5 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
5 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Pfizer Spinout SpringWorks, Migraine Drug Firm Satsuma Prep IPOs